The 2026 At-Home Ketamine Cost Study: What Treatment Actually Costs

At-home ketamine therapy costs between roughly $129 and $500 per month in 2026, depending on the provider and the treatment model. Over a full year, at-home programs run about $1,500 to $6,000, while in-clinic care for the same condition (IV infusion series or Spravato) commonly runs $7,000 to $15,000 or more. In other words, the at-home route is typically 60 to 90 percent cheaper per year than clinic-based ketamine, and the gap is the single most important number most patients never see laid out clearly.

I am a prescribing physician who runs an at-home program, so I have an obvious interest here, which is exactly why this study sticks to published pricing, states its method plainly, and shows the full field rather than a self-serving slice. If you are comparing options or writing about this space, the tables below are meant to be cited directly.

Methodology

• Scope: the five most visible at-home (telehealth) ketamine programs serving U.S. patients, plus two in-clinic benchmarks (IV infusion and Spravato) and one drug-therapy benchmark (standard antidepressants).
• Prices: collected from each provider's public pricing pages and program materials as of September 2026, in U.S. dollars, for adult self-pay patients. Where a provider lists a range or a first-course versus maintenance price, both are shown.
• Normalization: because programs bill differently (per month, per session, per course), every price is also expressed as an approximate annual cost for a typical first year of active treatment, so the models can be compared on one axis.
• What is excluded: lab work, optional therapy add-ons, and shipping are noted where they apply but are not baked into the headline figures, because they vary by patient.
• Caveat: prices change. This is a point-in-time snapshot for September 2026; verify current pricing with each provider before making a decision.

The data: at-home ketamine pricing, 2026

At-home programs cluster into two economic models. Daily low-dose (Joyous) is the cheapest because it skips the structured-session overhead. Session-based programs (Mindbloom, Innerwell, Better U) cost more because they wrap the medication in a guided-session framework and, in some cases, therapist time. Physician-led sublingual (Discreet Ketamine) sits in between on price while emphasizing continuity with one prescribing physician. For a fuller side-by-side of what each model actually includes, see the best at-home ketamine programs review and the detailed cost comparison.

How at-home compares with in-clinic ketamine

This is where the numbers diverge sharply.

The in-clinic premium is not mainly the drug. It is the facility, the staff, and the monitoring time: IV infusion and Spravato both require you to be in a clinic under observation, and that overhead is what you are paying for. Spravato is the one route insurance commonly covers, which can offset its high sticker price, but coverage requires prior authorization and still leaves copays. I break down that trade-off in Spravato vs. compounded ketamine.

For context against the older standard of care: a generic antidepressant (SSRI/SNRI) can cost as little as $4 to $50 per month, which is cheaper than any ketamine option. The reason patients consider ketamine anyway is that it works through a different mechanism and often helps when antidepressants have not. The relevant cost question is therefore not "ketamine vs. an SSRI," but "at-home ketamine vs. in-clinic ketamine," and there the at-home route wins decisively on price.

Key findings

• At-home ketamine is 60 to 90 percent cheaper per year than in-clinic ketamine. A representative at-home year ($1,500–$6,000) versus a representative IV-infusion or Spravato year ($7,000–$15,000+).
• The cheapest at-home option is roughly 4 to 10 times less than a Spravato year before insurance. Daily low-dose at ~$1,550/year versus Spravato often exceeding $10,000 pre-insurance.
• Within at-home care, the price spread is about 4x ($129/mo to ~$500/mo), and it tracks the model: daily low-dose is cheapest, therapist-led session programs are most expensive.
• Model, not brand, drives price. Two programs with similar names can differ by hundreds of dollars a month purely because one includes therapist time and one does not.
• The real out-of-pocket number is lower than the sticker for most patients, because at-home ketamine is HSA/FSA-eligible.

The number almost no one factors in: HSA/FSA

Because at-home ketamine is a cash-pay medical expense, most patients can pay with a pre-tax HSA or FSA, which effectively discounts the cost by roughly 20 to 35 percent depending on tax bracket. Applied to the table above, a $250/month program has an effective cost closer to $160 to $200 per month after the tax advantage. That single fact changes the affordability math more than switching providers does. The mechanics, including the letter of medical necessity some administrators request, are in the HSA and FSA guide. And if cost is the deciding factor, the cheapest ketamine therapy options for 2026 rank the field by total spend.

Cite this study

If you reference these figures, please cite them as: "2026 At-Home Ketamine Cost Study, Discreet Ketamine (Dr. Ben Soffer), September 2026," linking to this page. The data is free to quote with attribution. If you are a journalist or researcher and need the underlying breakdown or a comment, the practice can be reached through the site.

Frequently Asked Questions

How much does at-home ketamine therapy cost in 2026?

At-home ketamine therapy costs roughly $129 to $500 per month in 2026, or about $1,500 to $6,000 for a first year of active treatment, depending on the provider and whether the model is daily low-dose, physician-led sublingual, or guided-session based.

Is at-home ketamine cheaper than in-clinic ketamine?

Yes, substantially. At-home telehealth programs run about $1,500 to $6,000 per year, while in-clinic IV infusion series or Spravato commonly run $7,000 to $15,000 or more, making at-home care roughly 60 to 90 percent cheaper per year. The difference is largely facility and monitoring overhead, not the drug itself.

What is the cheapest at-home ketamine program?

Among the major programs, the daily low-dose model (Joyous, about $129/month) is the lowest-cost option. Physician-led sublingual programs like Discreet Ketamine (about $250/month, lower with multi-month plans) sit in the middle, and therapist-led session programs are the most expensive.

Does insurance cover at-home ketamine, and can I use an HSA or FSA?

Commercial insurance generally does not cover compounded at-home ketamine. However, because it is a prescribed medical expense, most patients can pay with a pre-tax HSA or FSA, which effectively reduces the cost by about 20 to 35 percent. Spravato, administered in-clinic, is the ketamine route most commonly covered by insurance.

Why does at-home ketamine cost less than an in-clinic infusion?

The medication is a small part of the total. In-clinic IV infusions and Spravato require a facility, clinical staff, and a monitoring period after each dose, and that overhead is the main driver of their higher cost. At-home sublingual treatment removes the facility and staffing cost, which is why the annual price is far lower.